BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7636250)

  • 1. Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis.
    Yelton DE; Rosok MJ; Cruz G; Cosand WL; Bajorath J; Hellström I; Hellström KE; Huse WD; Glaser SM
    J Immunol; 1995 Aug; 155(4):1994-2004. PubMed ID: 7636250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of BR96 binding sites for antigen and anti-idiotype by codon-based scanning mutagenesis.
    Rosok MJ; Eghtedarzadeh-Kondri M; Young K; Bajorath J; Glaser S; Yelton D
    J Immunol; 1998 Mar; 160(5):2353-9. PubMed ID: 9498776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of the relative affinities of antibody fragments expressed in Escherichia coli by enzyme-linked immunosorbent assay.
    Watkins JD; Beuerlein G; Pecht G; McFadden PR; Glaser SM; Huse WD
    Anal Biochem; 1997 Nov; 253(1):37-45. PubMed ID: 9356139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions.
    Finlay WJ; Cunningham O; Lambert MA; Darmanin-Sheehan A; Liu X; Fennell BJ; Mahon CM; Cummins E; Wade JM; O'Sullivan CM; Tan XY; Piche N; Pittman DD; Paulsen J; Tchistiakova L; Kodangattil S; Gill D; Hufton SE
    J Mol Biol; 2009 May; 388(3):541-58. PubMed ID: 19285987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.
    Schier R; McCall A; Adams GP; Marshall KW; Merritt H; Yim M; Crawford RS; Weiner LM; Marks C; Marks JD
    J Mol Biol; 1996 Nov; 263(4):551-67. PubMed ID: 8918938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural convergence of antibody binding of carbohydrate determinants in Lewis Y tumor antigens.
    Ramsland PA; Farrugia W; Bradford TM; Mark Hogarth P; Scott AM
    J Mol Biol; 2004 Jul; 340(4):809-18. PubMed ID: 15223322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody engineering by codon-based mutagenesis in a filamentous phage vector system.
    Glaser SM; Yelton DE; Huse WD
    J Immunol; 1992 Dec; 149(12):3903-13. PubMed ID: 1460281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of an Ig VH idiotope that results in specific homophilic binding and increased avidity for antigen.
    Yan X; Evans SV; Kaminki MJ; Gillies SD; Reisfeld RA; Houghton AN; Chapman PB
    J Immunol; 1996 Aug; 157(4):1582-8. PubMed ID: 8759742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Directed evolution, phage display and combination of evolved mutants: a strategy to recover the neutralization properties of the scFv version of BCF2 a neutralizing monoclonal antibody specific to scorpion toxin Cn2.
    Juárez-González VR; Riaño-Umbarila L; Quintero-Hernández V; Olamendi-Portugal T; Ortiz-León M; Ortíz E; Possani LD; Becerril B
    J Mol Biol; 2005 Mar; 346(5):1287-97. PubMed ID: 15713481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-function studies of anti-3-fucosyllactosamine (Le(x)) and galactosylgloboside antibodies.
    Snyder JG; Dinh Q; Morrison SL; Padlan EA; Mitchell M; Yu-Lee LY; Marcus DM
    J Immunol; 1994 Aug; 153(3):1161-70. PubMed ID: 7913110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection.
    Schier R; Bye J; Apell G; McCall A; Adams GP; Malmqvist M; Weiner LM; Marks JD
    J Mol Biol; 1996 Jan; 255(1):28-43. PubMed ID: 8568873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of loss and change of specificity resulting from random mutagenesis of an antibody VH region.
    Casson LP; Manser T
    J Immunol; 1995 Dec; 155(12):5647-54. PubMed ID: 7499849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro antibody maturation. Improvement of a high affinity, neutralizing antibody against IL-1 beta.
    Jackson JR; Sathe G; Rosenberg M; Sweet R
    J Immunol; 1995 Apr; 154(7):3310-9. PubMed ID: 7897213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
    Wu H; Nie Y; Huse WD; Watkins JD
    J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.
    Giles I; Lambrianides N; Latchman D; Chen P; Chukwuocha R; Isenberg D; Rahman A
    Arthritis Res Ther; 2005; 7(1):R47-56. PubMed ID: 15642142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
    Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
    J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational analysis of avidity and fine specificity of anti-levan antibodies.
    Brorson K; Thompson C; Wei G; Krasnokutsky M; Stein KE
    J Immunol; 1999 Dec; 163(12):6694-701. PubMed ID: 10586066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies.
    Wang X; Campoli M; Ko E; Luo W; Ferrone S
    J Immunol Methods; 2004 Nov; 294(1-2):23-35. PubMed ID: 15604013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Affinity maturation of a V(H)H by mutational hotspot randomization.
    Yau KY; Dubuc G; Li S; Hirama T; Mackenzie CR; Jermutus L; Hall JC; Tanha J
    J Immunol Methods; 2005 Feb; 297(1-2):213-24. PubMed ID: 15777944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants.
    De Pascalis R; Gonzales NR; Padlan EA; Schuck P; Batra SK; Schlom J; Kashmiri SV
    Clin Cancer Res; 2003 Nov; 9(15):5521-31. PubMed ID: 14654532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.